Document is current
Any future updates will be listed below
-
Authors
Møller, Pal
Seppälä, Toni T.
Ahadova, Aysel
Crosbie, Emma J.
Holinski-Feder, Elke
Scott, Rodney
Haupt, Saskia
Möslein, Gabriela
Winship, Ingrid
Broeke, Sanne W. Bajwa-ten
Kohut, Kelly E.
Ryan, Neil
Bauerfeind, Peter
Thomas, Laura E.
Evans, D. Gareth
Aretz, Stefan
Sijmons, Rolf H.
Half, Elizabeth
Heinimann, Karl
Horisberger, Karoline
Monahan, Kevin
Engel, Christoph
Cavestro, Giulia Martina
Fruscio, Robert
Abu-Freha, Naim
Zohar, Levi
Laghi, Luigi
Bertario, Lucio
Bonanni, Bernardo
Tibiletti, Maria Grazia
Lino-Silva, Leonardo S.
Vaccaro, Carlos
Valle, Adriana Della
Rossi, Benedito Mauro
da Silva, Leandro Apolinário
de Oliveira Nascimento, Ivana Lucia
Rossi, Norma Teresa
Dębniak, Tadeusz
Mecklin, Jukka-Pekka
Bernstein, Inge
Lindblom, Annika
Sunde, Lone
Nakken, Sigve
Heuveline, Vincent
Burn, John
Hovig, Eivind
Kloor, Matthias
Sampson, Julian R.
Dominguez-Valentin, Mev
,
-
Funding
Funding for this research was provided by:
The Norwegian Cancer Society (Contract 194751-2017, Contract 194751-2017, Contract 194751-2017, Contract 194751-2017)
Cancer Society Finland, Sigrid Juselius Foundation, Jane and Aatos Erkko Foundation, Relander Foundation and the Academy of Finland.
EJC and DGE are funded by the Manchester National Institute for Health Research (NIHR) Biomedical Research Centre (IS-BRC-1215-20007, IS-BRC-1215-20007)
JRS received grant support previously from Health and Care Research Wales for the Wales Gene Park
- License Information
-
More Information
Article History
Received: 13 August 2023
Accepted: 29 September 2023
First Online: 11 October 2023
Declarations
:
: Not applicable.
: Toni T. Seppälä: Healthfund Finland (CEO and stock holding), LS Cancer Diag (advisory board and stock holding) and Amgen Finland (speaker honorarium).
